Crossmark

Cannabis for the Treatment of Epilepsy: an Update

Crossref DOI link: https://doi.org/10.1007/s11910-018-0882-y

Published Online: 2018-09-08

Published Print: 2018-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gaston, Tyler E.

Szaflarski, Jerzy P.
License Information

Text and Data Mining valid from 2018-09-08
More Information

Article History

First Online: 8 September 2018

Compliance with Ethical Standards

:

: Dr. Szaflarski reports personal fees from GW Pharmaceuticals; grants and personal fees from Serina Therapeutics, Inc., during the conduct of the study; personal fees from SK Life Sciences; personal fees from LivaNova Inc.; personal fees from Lundbeck; personal fees from NeuroPace Inc.; personal fees from Upsher-Smith Laboratories, Inc.; grants and personal fees from SAGE Pharmaceuticals; grants from UCB Pharma; grants from Biogen; and grants from Eisai Inc., outside the submitted work.Dr. Gaston reports personal fees from GW Pharmaceuticals, during the conduct of the study.

: This article does not contain any studies with human or animal subjects performed by any of the authors.